skip to content »

Lester and Sue Smith Breast Center

Houston, Texas

The Lester and Sue Smith Breast Center's mission is to improve prevention, diagnosis and treatment of breast disease.
Lester & Sue Smith Breast Center
not shown on screen

Rachel Schiff, Ph.D. - Publications

Selected Publications

Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM, Schiff R: Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 5;95(5):353-61, 2003. [PDF]

Schiff R, Massarweh S, Shou J, Osborne CK: Breast cancer endocrine resistance – How growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res. 9(1 Pt 2): 447S-54S, 2003.

Lee AV, Schiff R, Cui X, Sachdev D, Yee D, Gilmore A, Streuli C, Oesterrich S, Hadsell D: New mechanisms of signal transduction inhibitor action: Receptor tyrosine kinase downregulation and blockade of signal transactivation. Clin Cancer Res. 9(1 Pt 2):516S-23S, 2003.

Morrison AJ, Herrera RE, Heinsohn EC, Schiff R, Osborne CK: Dominant-negative nuclear receptor corepressor relieves transcriptional inhibition of retinoic acid receptor but does not alter the agonist/antagonist activities of the tamoxifen-bound estrogen receptor. Mol Endocrinology 17:1543-54, 2003. [PDF]

Fuqua SA, Schiff R, Parra I, Moore JT, Mohsin SK, Osborne CK, Clark GM, Allred DC. Estrogen receptor beta protein in human breast cancer: Correlation with clinical tumor parameters. Cancer Res. 63(10):2434-2439, 2003. [PDF]

Schiff R, Chamness GC, Brown PH. Advances in breast cancer treatment and prevention: Preclinical studies on aromatase inhibitors and new SERMs. Breast Cancer Res. 5(5): 228-231, 2003. [PDF]

Oesterreich S, Deng W, Jiang S, Cui X, Ivanova M, Schiff R, Kang K, Hadsell D, Behrens J, Lee AV. Estrogen-mediated downregulation of E-cadherin in breast cancer cells. Cancer Res. 63(17):5203-5208, 2003. [PDF]

Osborne CK, Schiff R. Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer. Breast. 12(6): 362-367, 2003.

Schiff R, Massarweh S, Shou J, Bharwani L, Mohsin SK, Osborne CK. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res. 10(1 pt2): 331S-6S, 2004.

Come SE, Buzdar AU, Arteaga CL, Bissell MJ, Brown MA, Ellis MJ, Goss PE, Green JE, Ingle JN, Lee AV, Medina D, Nicholson RI, Santen RJ, Schiff R, Hart CS. Proceedings of the third international conference on recent advances and future directions in endocrine manipulation of breast cancer: conference summary statement. Clin Cancer Res. 10 (1 pt2): 327S-330S, 2004.

Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R. Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER-2/neu crosstalk in ER/HER2-positive breast cancer. JNCI 96(12):926-935, 2004. [PDF]

Osborne CK, Shou J, Massarweh S, Schiff R. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Can Res 11(2):865s-870s, 2005. [PDF]

Osborne CK, Schiff R. Estrogen receptor biology: Continuing progress and therapeutic implications. JCO. 23(8):1616-22, 2005. [PDF]

Mohsin SK, Weiss HL, Gutierrez MC, Chamness GC, Schiff R, DiGiovanna MP, Wang C-X, Hilsenbeck SG, Osborne CK, Allred DC, Elledge R, Chang JC. Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol. 10;23(11):2460-8, 2005. [PDF]

Cui X, Schiff R, Arpino G, Osborne CK, Lee AV. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. JCO. 23(30):7721-7735, 2005. [PDF]

Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, Dowsett M. Molecular changes in tamoxifen-resistant breast cancer: Relationship between ER, HER2, and p38 MAPK. J Clin Oncol. 23(11):2469-76, 2005. [PDF]

Nabha SM, Glaros S, Hong M, Lykkesfeldt AE, Schiff R, Osborne CK, Reddy KB. Upregulation of PKC-delta contributes to anti-estrogen resistance in mammary tumor cells. Oncogene 28;24(19):3166-76, 2005. [PDF]

Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM. Estrogen receptor-positive, progesterone receptor-negative breast cancer: Association with growth factor receptor expression and tamoxifen resistance. JNCI 97(17):1254-1261, 2005. [PDF]

Schiff R, Osborne CK. Review. Endocrine and hormone therapy in breast cancer: New insight into estrogen receptor-alpha function and its implication for endocrine therapy resistance in breast cancer. Breast Cancer Res 7:205-211, 2005.

Osborne CK, Schiff R. Aromatase Inhibitors: Future directions. J Steroid Biochemist. 95(1-5):183-187, 2005.

Zhang X, Podsypanina K, Huang S, Mohsin SK, Chamness GC, Hatsell S, Cowin P, Schiff R, Li Y. Estrogen receptor positivity in mammary tumors of Wnt-1 transgenic mice is influenced by collaborating oncogenic mutations. Oncogene 16;24(26):4220-31, 2005. [PDF]

Schiff R, Massarweh S, Shou J, Bharwani L, Arpino G, Rimawi M, Osborne CK. Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: Implicated role of growth factor signaling and estrogen receptor coregulators. Cancer Chemo. Pharmacol 56S: 10-20, 2005. [PDF]

Osborne CK, Schiff R, Arpino G, Lee A, Hilsenbeck SG. Endocrine responsiveness: Understanding how progesterone receptor can be used to select endocrine therapy. Breast 14(6):458-465, 2005. [PDF]

Dowsett M, Johnston S, Martin LA, Salter J, Hills M, Detre S, Gutierrez MC, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, Smith I. Growth factor signaling and response to endocrine therapy: The Royal Marsden Experience. Endocr Relat Cancer. 12(Suppl 1):S113-7, 2005. [PDF]

Osborne CK, Shou J, Massarweh S, Schiff R. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Can Res 11(2):865s-870s, 2005.

Harrington WR, Kim SH, Funk CC, Madak-Erdogan Z, Schiff R, Katzenellenbogen JA, Katzenellenbogen BS. Estrogen dendrimer conjugates that preferentially activate extranuclear, non-genomic versus genomic pathways of estrogen action. Mol Endocrinol. 20(3):491-502, 2006. [PDF]

Schiff R, Lee AV. Can biomarkers direct the optimal use of aromatase inhibitors versus selective estrogen receptor modulators. Nat Clin Pract Oncol 3(3):134-5, 2006 [PDF]

Divova J, Kuiatse I, Lazard Z, Weiss H, Vreeland F, Hasell DL, Schiff R, Osborne CK, Lee AV. The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth. Breast Cancer Res. Treat. 98(3):315-27, 2006. [PDF]

Massarweh S, Osborne CK, Shou J, Wakeling AE, Rimawi A, Mohsin S, Hilsenbeck S, Schiff R. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. Cancer Res. 66(16) 8266-73, 2006. [PDF]

Massarweh S, Schiff R. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk. Endocr Relat Cancer. 2006 Dec; 13 Suppl 1:S15-24. [PDF]

Massarweh S, Schiff R. Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities. Clin. Cancer Res. 2007 Apr 1;13(7):1950-4. [PDF]

Arpino G, Gutierrez C, Weiss H, Rimawi, M, Massarweh S, Bharwani L, De Placido S, Osborne CK, Schiff R. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J Natl Cancer Inst. 2007 May2;99(9):694-705. [PDF]

Sampath L, Kwon S, Ke Shi, Wang W, Schiff R, Mawad M, Sevick-Muraca E: Dual-labeled Trastuzumab-Based Imaging Agent for the Detection of Human Epidermal Growth Factor Receptor 2 Overexpression in Breast Cancer. J Nucl Med. 2007 48:1501-1510. [PDF]

Lopez-Tarruella, S., and Schiff, R. The dynamics of estrogen receptor status in breast cancer: Reshaping the paradigm. Clin. Cancer Res. Dec. 1;13(23): 6921-5, 2007. [PDF]

Massarweh, S., Osborne, C.K., Creighton, C., Qin, L., Tsimelzon, A., Huang, S., Weiss, H., Rimawi, M., and Schiff, R. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classical estrogen receptor genomic function. Cancer Research. (68) 826-833 Feb. 2008. [PDF]

Creighton, CJ.,Kent Osborne C., van de Vijver MJ., Foekens JA., Klijin JG., Horlings HM., Nuyten D., Wang Y., Zhang Y., Chamness GC., Hilsenbeck SG., Lee AV., Schiff R. Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res. Treat. 2008 Apr 19. [Epub ahead of print] [PDF]

Book Chapters

Fuqua, S.A.W., Schiff, R. The Biology of Estrogen Receptor. Diseases of the Breast, 3 rd Edition, Harris, J.R., Lippman, M.E., Morrow, M. and Osborne, C.K., eds. Lippincott Williams & Wilkins, Philadelphia, pp. 585-602, 2004.

Osborne, C.K., Schiff, R.. Crosstalk Between Estrogen Receptor and Growth-Factor-Receptor Pathways as a Mechanism of Endocrine Therapy Resistance. Advance in Endocrine Therapy of Breast Cancer. Ingle, J.N., Dowsett, M. eds. New York, Marcel Dekker, Inc. 2004, pp 215-228.

Schiff R and Fuqua SAW: The importance of estrogen receptor in breast cancer. In: Breast Cancer: Prognosis, Treatment and Prevention. Pasqualini JR, ed. New York: Marcel Dekker Inc., 2002 pp149-186.

E-mail this page to a friend